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Abstract. 
 
a
 
-Dystrobrevin is both a dystrophin homo-
logue and a component of the dystrophin protein com-
plex. Alternative splicing yields five forms, of which 
two predominate in skeletal muscle: full-length 
 
a
 
-dys-
trobrevin-1 (84 kD), and COOH-terminal truncated 
 
a
 
-dystrobrevin-2 (65 kD). Using isoform-specific anti-
bodies, we find that 
 
a
 
-dystrobrevin-2 is localized on the 
sarcolemma and at the neuromuscular synapse, where, 
like dystrophin, it is most concentrated in the depths of 
the postjunctional folds. 
 
a
 
-Dystrobrevin-2 preferen-
tially copurifies with dystrophin from muscle extracts. 
In contrast, 
 
a
 
-dystrobrevin-1 is more highly restricted 
to the synapse, like the dystrophin homologue utro-
phin, and preferentially copurifies with utrophin. In 
yeast two-hybrid experiments and coimmunoprecipita-
tion of in vitro–translated proteins, 
 
a
 
-dystrobrevin-2 
binds dystrophin, whereas 
 
a
 
-dystrobrevin-1 binds both 
dystrophin and utrophin. 
 
a
 
-Dystrobrevin-2 was lost 
from the nonsynaptic sarcolemma of dystrophin-defi-
 
cient 
 
mdx
 
 mice, but was retained on the perisynaptic 
sarcolemma even in mice lacking both utrophin and 
dystrophin. In contrast, 
 
a
 
-dystrobrevin-1 remained syn-
aptically localized in 
 
mdx
 
 and utrophin-negative mus-
cle, but was absent in double mutants. Thus, the distinct 
distributions of 
 
a
 
-dystrobrevin-1 and -2 can be partly 
explained by specific associations with utrophin and 
dystrophin, but other factors are also involved. These 
results show that alternative splicing confers distinct 
properties of association on the 
 
a
 
-dystrobrevins.
Key words: dystrophin complex • neuromuscular 
junction • postsynaptic folds • high revolution immu-
nofluorescence • isoform-specific antibodies
 
M
 
utations
 
 that disrupt the expression or function
of dystrophin cause Duchenne muscular dystro-
phy, a myopathy that leads to muscle cell degen-
eration (3, 34). Dystrophin is a large, 427-kD protein com-
posed of an NH
 
2
 
-terminal actin-binding domain (33), a
series of spectrin-like repeats, and a cysteine-rich (CR)
 
1
 
region, and a COOH-terminal (CT) domain, both of
which contain sites for interaction with other proteins (3).
Association between dystrophin and 
 
b
 
-dystroglycan, a
transmembrane protein, provides a link to the extracellu-
lar 
 
a
 
-dystroglycan, which in turn binds laminin and agrin
(for review see reference 33). Thus, one function of the
dystrophin complex is to link the extracellular matrix to
cortical actin. A group of four proteins, the sarcoglycans,
are also part of the dystrophin complex. Although the
function of the sarcoglycans are unknown, they are altered
in several of the limb girdle muscular dystrophies in which
dystrophin is found to be normal (40, 42). Other proteins
in the complex include dystrobrevin and the syntrophins
(25, 28, 29, 36).
Dystrophin is expressed at highest levels in skeletal
muscle, where it may serve to stabilize the sarcolemma
during cycles of muscle contraction and relaxation. In ad-
dition to this structural role, however, the dystrophin com-
plex may also be involved in membrane signaling. Two
lines of evidence support this idea. First, Grb2, a modular
protein that mediates signals generated by receptor ty-
rosine kinases, can bind via its SH3 domain to 
 
b
 
-dystrogly-
can (44). A second group of modular adapter proteins, the
syntrophins, are associated directly with dystrophin via the
CT domain and are major components of the dystrophin
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1. 
 
Abbreviations used in this paper
 
: Ab, polyclonal antibody; AChR, ace-
tylcholine receptor; CR, cysteine rich; CT, COOH-terminal; DRP, dystro-
phin-related protein; DUR, dystrobrevin-unique region; NMJ, neuromus-
cular junction; PDZ, protein domain originally identified in postsynaptic
density-95, discs large, ZO-1; 
 
a
 
-BgTx, 
 
a
 
-bungarotoxin.
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complex (1, 4, 5, 25, 28, 45). Three syntrophins, each en-
coded by separate genes, have a common domain struc-
ture. In addition to the COOH-terminal syntrophin-
unique domain, the remainder of the protein is composed
of two pleckstrin homology domains and one PDZ domain
(a domain originally identified in postsynaptic density-95,
discs large, ZO-1) (2, 5). In skeletal muscle, the syntrophin
PDZ domain binds neuronal nitric oxide synthase (12) or
voltage-activated sodium channels (21, 37).
Four other proteins related to dystrophin but encoded
by separate genes have been identified. Utrophin is most
closely similar to dystrophin and is widely expressed, al-
though at only low levels in skeletal muscle (41). Dystro-
phin-related protein (DRP)2 lacks the actin-binding domain
and most of the spectrin-like repeats, and is expressed at
high levels in brain (32). Together, dystrophin, utrophin,
and DRP2 comprise a subfamily, based on sequence com-
parison. A second subfamily is composed of the dystrobre-
vins (29). 
 
a
 
-Dystrobrevin, first discovered as an 87-kD ty-
rosine-phosphorylated protein in 
 
Torpedo
 
 electric organ
(14), has no spectrin-like repeats, but contains a CRCT
domain that binds syntrophins (11, 35, 43, 46). In addition,
 
a
 
-dystrobrevin has a unique COOH-terminal extension of
 
z
 
180 amino acids, the dystrobrevin unique region (DUR)
that contains multiple sites for phosphorylation on ty-
rosine. Several forms of 
 
a
 
-dystrobrevin are generated by
alternative splicing, including two that lack the DUR (10,
35). A second gene encoding a closely related protein,
 
b
 
-dystrobrevin, has recently been described (11, 29, 30).
 
b
 
-Dystrobrevin is quite similar to 
 
a
 
-dystrobrevin, except
that the DUR is significantly shorter.
 
a
 
- and 
 
b
 
-dystrobrevins are unique among the dystro-
phin family proteins in that they are both related to and
associated with dystrophin (28, 29, 36). Coiled-coils in the
CT domains of each protein mediate heterodimerization
between the dystrobrevins and dystrophin (36). Thus, a re-
fined model for the dystrophin and utrophin complexes
contains two syntrophins, one bound to dystrophin (or
utrophin) and one to dystrobrevin (28, 36). The presence
of two syntrophins may provide a platform on which mul-
ticomponent signaling complexes can be assembled.
A membrane site that is particularly rich in dystrophin
family proteins is the neuromuscular junction (NMJ) (for
review see reference 38). Although utrophin is expressed
only at very low levels in skeletal muscle as a whole, it is
concentrated at and localized to the crests of the junc-
tional folds in a distribution that closely matches that of
nicotinic acetylcholine receptors (AChRs) and rapsyn (8,
27). Dystrophin is also concentrated at neuromuscular
synapses but is restricted to the depths of the folds along
with voltage-activated sodium channels (8, 13, 18, 39).
Here, we have studied the distribution in skeletal muscle
of two isoforms of 
 
a
 
-dystrobrevin generated by alternative
splicing (10, 35). 
 
a
 
-Dystrobrevin-1 contains the COOH-
terminal extension, while 
 
a
 
-dystrobrevin-2 lacks this se-
quence. 
 
a
 
-Dystrobrevin-1 is highly localized to the NMJ,
while 
 
a
 
-dystrobrevin-2 is concentrated at the synapse but
also is present on the sarcolemma. In part, these unique
distributions probably result from inherent specificities of
the association of the two dystrobrevin isoforms with utro-
phin and dystrophin. However, our studies with skeletal
muscle from mice lacking dystrophin, utrophin, or both
 
proteins (24) suggest that additional regulatory factors,
possibly including interactions with other proteins, are
necessary for targeting of isoforms of dystrobrevin to dif-
ferent locations within the postsynaptic membrane.
 
Materials and Methods
 
Antibodies
 
Anti-dystrobrevin. 
 
mAb 13H1 was prepared against Torpedo dystrobrevin
(14) and was a gift from J.B. Cohen (Harvard Medical School, Cambridge,
MA). Rabbit polyclonal antibodies (Abs) were prepared against synthetic
dystrobrevin peptides with a terminal cysteine coupled to keyhole limpet
hemocyanin according to standard methods (Covance Inc., Denver, PA).
Isoform-specific synthetic peptides C-DMVPEDGDPYTQPEDGNY-
ENE and C-EEYLKQKLQDEAYQVSLQG, which correspond to amino
acids 638–658 and 670–688 of the mouse 
 
a
 
-dystrobrevin-1 sequence origi-
nally published by Blake et al. (see reference 10), were used to produce
Ab 
 
a
 
DB638 and Ab 
 
a
 
DB670, respectively. The preparation of Ab 
 
a
 
DB2
against the peptide C-GVSYVPYCRS-COOH corresponding to the
COOH-terminal 10 amino acids unique to 
 
a
 
-dystrobrevin-2 has been de-
scribed (29). All polyclonal antibodies were affinity purified from serum
with relevant peptide coupled to Affi-Gel-10 or -15 (Bio-Rad Laborato-
ries, Hercules, CA). The binding activity of each Ab was blocked by pre-
incubation with the appropriate peptide (100 
 
m
 
M) for 30 min before use.
 
Anti-syntrophin. 
 
mAb SYN1351 was raised against 
 
Torpedo
 
 syntrophin
(19) and has been shown to recognize all three mammalian syntrophin iso-
forms (28).
 
Anti-dystrophin. 
 
Ab DYS3669 was described previously (28). Mandra-1
was purchased from Sigma Chemical Co. (St. Louis, MO). DYS1 and
DYS2 were purchased from Novacastra (Newcastle upon Tyne, UK).
 
Anti-utrophin. 
 
Ab UTR3165 was prepared previously (25). mAb
MANCHO-3 was a gift of G.E. Morris (26). mAb DRP1 was purchased
from Novacastra (Newcastle upon Tyne, UK).
 
Animals
 
Control (C57BL/10ScSn) and 
 
mdx
 
 mice (C57BL/10ScSn 
 
mdx
 
) were ob-
tained from Jackson Laboratories (Bar Harbor, ME). 
 
utrn
 
2
 
/
 
2
 
 and 
 
mdx
 
/
 
utrn
 
2/2
 
 mice have been described (23, 24).
 
Immunohistochemistry
 
Unfixed hind limb skeletal muscles were flash frozen in liquid nitrogen-
cooled isopentane. Cryosections (7 
 
m
 
m) were labeled with primary antibodies
at 30 nM as described previously (23, 28). 
 
a
 
-Bungarotoxin (
 
a
 
-BgTx) conju-
gated to BODIPY was used at 1:300 (Molecular Probes Inc., Eugene, OR).
High resolution localization of the dystrobrevins by confocal micros-
copy was done on mouse sternomastoid muscle. 
 
a
 
-Dystrobrevin-1 and
 
a
 
-dystrobrevin-2 were localized at NMJs using the respective rabbit anti-
bodies, followed by Texas red–conjugated secondary and tertiary antibod-
ies (Jackson ImmunoResearch). AChR were labeled with biotin-conju-
gated 
 
a
 
-Bgtx followed by CY2-conjugated streptavidin (Molecular Probes
Inc.). Appropriate control experiments confirmed the specificity of all sec-
ondary and tertiary antibodies.
Mouse sternomastoid muscles were dissected into physiological saline
containing 0.5% PFA, fixed for 30 min, and then washed in saline. Blocks
containing the innervation zone were flash frozen for microtomy. Cryostat
sections (15 
 
m
 
m) were labeled with antibodies as described above, fixed in
4% PFA, and embedded in Araldite. Sections (100-nm thick) of small
junction-containing areas were prepared with an ultramicrotome
equipped with a diamond knife and mounted on No. 1.5 coverslips with-
out mounting medium. Two-channel images were recorded with a Leica
TCS-NT confocal microscope. To verify that bleed-through of signal from
 
a
 
-BgTx labeling (green) was not significantly contaminating the signal
from antibody labeling (red), selected images were taken in the identical
way except that either the 568-nm or the 488-nm excitation beam was
turned off at the acoustically tunable filter.
 
Immunoaffinity Purifications and Immunoblotting
 
Immunoaffinity purifications and immunoblotting were performed as pre-
viously described (28). 
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Yeast Two-Hybrid Assay
 
cDNAs encoding full-length 
 
a
 
-dystrobrevin-1 and the CT region of utro-
phin (CTDRP) (amino acids 2,753–3,432) were specifically amplified by
PCR as previously described (35) and cloned into both the pGBT9 and
the pGAD vectors for the two-hybrid assay (CLONTECH, Palo Alto,
CA). The 
 
a
 
-dystrobrevin-2 construct and the COOH-terminal dystrophin
construct corresponding to exons 61–79 (DYS e61–79), were previously
described (35). The yeast two-hybrid analysis was performed according
to published methods (17). The HF7c yeast strain, containing two
Gal4-inducible reporter genes, 
 
HIS3
 
 and 
 
LacZ
 
, was transformed simulta-
neously with both a DNA-binding domain plasmid (trp
 
2
 
) and a transacti-
vating domain plasmid (leu
 
2
 
). Double transformants were plated onto
selection plates lacking tryptophan, leucine, and histidine. After 5 d at
30
 
8
 
C, the colonies that grew on this selective medium (His
 
1
 
 colonies) were
lifted onto 3-mm Whatman paper, immersed in liquid nitrogen for a few
seconds, and then layered onto a second piece of Whatman paper, humidi-
fied with 3 ml of Z buffer (60 mM Na
 
2
 
HPO
 
4
 
, 40 mM NaH
 
2
 
PO
 
4
 
, 10 mM
KCl, 1 mM MgSO
 
4
 
, 30 mM 
 
b
 
-mercaptoethanol, 5-bromo-4-chloroindolyl-
 
b
 
-D-galactoside [XGal]; final concentration of 2 mg/ml) for 8 h at room
temperature.
 
In Vitro Translation and Immunoprecipitation Assay
 
Full-length dystrobrevin (
 
a
 
-dystrobrevin-1) was amplified by PCR as pre-
viously described (36) and cloned into the expression vector pMGT. The
 
a
 
-dystrobrevin-2 construct, the COOH-terminal region of utrophin construct
(TDRII), and the COOH-terminal region of dystrophin construct (C2979)
have been described (4, 36). Proteins encoded by the dystrobrevin, dystro-
phin, and utrophin constructs were produced by in vitro transcription/
translation of the expression vector pMGT (4) using the TNT T7–coupled
reticulocyte lysate system (Promega Corp., Madison, Wl) in a reaction
volume of 50 
 
m
 
l as per the manufacturer’s protocol. Some reactions were
carried out in a reaction buffer containing 0.2 
 
m
 
Ci (4 
 
m
 
l) of 
 
l
 
-[U-
 
14
 
C]leu-
cine (
 
.
 
300 mCi/mmol; Amersham Corp., Arlington Heights, IL).
Coprecipitation assays were performed with protein taken directly
from the translation reactions. Aliquots (5 
 
m
 
l) of each protein of interest
were incubated together in 20 
 
m
 
l of TBST buffer (10 mM Tris, pH 8.0,
0.1% Tween 20, 150 mM NaCl). After 1.5–2 h of incubation on ice, 20 
 
m
 
l
of Ab (1:10 dilution in TBST) directed against one of the proteins (the
cognate protein) were added. After 1-h incubation on ice, interacting pro-
teins were precipitated by the addition of 50 
 
m
 
l of a 50% suspension of
protein G–Sepharose (Sigma Chemical Co.) and incubated for 30 min on
ice. The protein–antibody bead complexes were pelleted at 10,000 
 
g
 
 for 2
min at room temperature, and the supernatant was removed. The beads
were then washed three times with 1 ml of TBST buffer, and the pellet
was resuspended in 10 
 
m
 
l of 2
 
3 
 
SDS sample buffer, and stored at 
 
2
 
20
 
8
 
C.
All samples were separated by electrophoresis on SDS-PAGE gels, and
protein sizes were compared with [
 
14
 
C]methylated high molecular weight
standards (10–50 
 
m
 
Ci/mg) (Amersham Corp.). Gels were dried onto 3-mm
Whatman paper, and exposed to a storage phosphor plate for 1–7 d, which
was then scanned by a PhosphorImager (Molecular Dynamics, Sunnyvale,
CA) and analyzed with ImageQuant software (Molecular Dynamics).
 
Results
 
Isoform Specificity of Dystrobrevin Antibodies
 
Analysis of 
 
a
 
-dystrobrevin cDNA products predicts five
proteins. Four of these contain the coiled-coils and syntro-
phin-binding regions needed for assembly into dystro-
phin–dystrobrevin–syntrophin complexes (Fig. 1 
 
A
 
) (6, 10,
35). To investigate the distribution and protein associa-
tions of dystrobrevin isoforms, we prepared polyclonal an-
tibodies against isoform-specific peptides. Antibody 
 
a
 
DB2
was generated against a peptide corresponding to the
COOH-terminal 10 amino acids unique to 
 
a
 
-dystrobrevin-2
and -5 (Fig. 1 
 
A
 
). Antibodies 
 
a
 
DB638 and 
 
a
 
DB670 were
generated against peptides corresponding to regions of the
COOH-terminal tail unique to 
 
a
 
-dystrobrevin-1 and -4
(Fig. 1 A). Since none of these peptides are conserved in
the recently identified b-dystrobrevin (11, 29, 30), the anti-
bodies should be specific for a-dystrobrevin splice forms.
These antibodies were characterized by immunoblotting
of syntrophin–dystrophin–dystrobrevin preparations iso-
lated from skeletal muscle using a syntrophin antibody
(mAb SYN1351). A pan-specific dystrobrevin antibody
(14), DB13H1, recognized polypeptides of apparent mo-
lecular weights z84 kD and z65 kD, similar to the pre-
dicted values for a-dystrobrevins-1 and -2 (Fig. 1 B). Ab
aDB2 recognized only the z65-kD polypeptide, whereas
Abs  aDB638 and aDB670 labeled only the z84-kD
polypeptide (Fig. 1 B). In each case, labeling was judged to
be specific since preincubating the antibody with the ap-
propriate peptide eliminated all labeling (Fig. 1 B).
Two other isoforms predicted to bind syntrophin and
dystrophin are a-dystrobrevin-4 and -5. We did not detect
a-dystrobrevins of the size expected for these isoforms in
our syntrophin preparations from skeletal muscle. The
possibility remains that these proteins are present at low
levels, or in a form not associated with syntrophin. How-
ever, our results are consistent with the fact that a-dystro-
brevin-5 was not found in immunoblots of normal muscle
Figure 1. Antibodies to a-dystrobrevin isoforms in skeletal mus-
cle. (A) Schematic of the known a-dystrobrevin cDNAs identi-
fied in mouse (10) and human tissues (35). The coding region in-
cludes a syntrophin-binding region (for review see reference 20)
and a pair of coiled-coils (9). Abs were generated against pep-
tides (shown as bars) corresponding to regions specific for iso-
forms. Predicted molecular weights for mouse a-dystrobrevin-1
and -2 were calculated from the mouse sequences while a-dystro-
brevin-3, -4, and -5 were estimated based on the corresponding
sequences in human. (B) The specificities of dystrobrevin anti-
bodies were tested by immunoblot analysis. Dystrobrevin–dys-
trophin–syntrophin complexes were partially purified with mAb
SYN1351 from Triton X-100–solubilized skeletal muscle extracts
and immunoblotted with affinity-purified antibodies prepared
against sequences specific to a-dystrobrevin-2 (aDB2) or a-dys-
trobrevin-1 (aDB638, aDB670). Labeling with antibodies (2)
was eliminated by preincubation of the antibody with antigenic
peptide (1). Molecular weight markers are shown in kD.The Journal of Cell Biology, Volume 142, 1998 1272
tissue (10, 11) and with mRNA analysis showing that tran-
scripts corresponding to a-dystrobrevins-1 and -2 are ex-
pressed at high levels in skeletal muscle, while a-dystro-
brevins-4 and -5 as well as b-dystrobrevin mRNAs are
expressed at much lower levels (10, 29, 35).
Localization of a-Dystrobrevins in Skeletal Muscle
Previous immunofluorescence studies on skeletal muscle
found dystrobrevins on the sarcolemma, but with particu-
lar enrichment at the NMJ (10, 14). We now know that
these studies used antibodies that recognize both a-dystro-
brevin-1 and -2, as well as b-dystrobrevin (29). Using the
new antibodies described above, we examined the distri-
bution of a-dystrobrevin isoforms in skeletal muscle. Re-
gions rich in NMJs were identified with a-BgTx (Fig. 2, A,
C, E, G, I, and K). The anti–a-dystrobrevin-2 antibody
strongly labeled the sarcolemma with particular enrich-
ment at the NMJ (Fig. 2 B). In contrast, labeling with both
a-dystrobrevin-1 Abs (aDB638 and aDB670) was highly
restricted to the NMJ (Fig. 2, F and J). Occasionally, faint
but specific extrasynaptic labeling could be detected with
Abs aDB638 and aDB670 (not apparent in Fig. 2, F and J,
but can be seen in Fig. 5 B, panel b; and Fig. 6 A). Labeling
with each antibody was blocked by preincubation with the
antigenic peptide (Fig. 2, D, H, and L). Thus, two a-dys-
trobrevin isoforms generated by alternative splicing are
differentially targeted in skeletal muscle.
Immunoaffinity Purification of
Dystrobrevin Complexes
Dystrophin and utrophin complexes were partially puri-
fied from detergent extracts of skeletal muscle by immu-
noaffinity purification and analyzed by immunoblotting. It
should be noted that the bulk of utrophin in skeletal mus-
cle tissue is derived from non-muscle cells and not from
the postsynaptic membrane (31). Gel sample loadings
were adjusted to contain similar amounts of total syntro-
phin (Fig. 3, Anti-Syn). As previously found (28), dystro-
phin preparations were highly enriched in dystrophin but
were free of detectable utrophin (Fig. 3). Likewise, utro-
phin preparations were highly enriched in utrophin but
lacked detectable dystrophin. Dystrophin and utrophin
preparations contain approximately equal amounts of to-
tal dystrobrevin immunoreactivity (detected with the pan-
specific antibody DB13H1). However, the molecular mass
of these dystrobrevins was clearly distinct (Fig. 3). Dystro-
Figure 2. Localization of
a-dystrobrevin isoforms in
skeletal muscle. The dis-
tribution of a-dystrobrevins
in gastrocnemius skeletal
muscle was compared with
a-bungarotoxin (a-BgTx)
staining of AChRs (A, C, E,
G, I, and K). a-Dystrobre-
vin-2  antibodies (aDB2)
stained the entire sarcolemma
with particular concentration
at the NMJ (B). Abs aDB638
and aDB670 directed against
COOH-terminal tail of a-dys-
trobrevin-1 labeled NMJs
with little or no extrasynaptic
sarcolemmal labeling (F and
J). Labeling for each antibody
was dramatically reduced by
preincubation of antibody
with the appropriate antigenic
peptide (D, H, and L). Bar,
50  mm.
Figure 3. Preferential copurifi-
cation of a-dystrobrevin-1 with
utrophin and a-dystrobrevin-2
with dystrophin. Dystrophin (Dys)
and utrophin (Utr) complexes
were isolated from Triton
X-100–solubilized extracts of
mouse skeletal muscle with Ab
DYS3669 and with Ab UTR
3165, respectively. For immuno-
blotting, sample loads were ad-
justed to contain approximately
equal amounts of syntrophin,
detected by mAb SYN1351
(Anti-Syn). Immunoblotting these
preparations with MANDRA-1
(Anti-Dys) and MANCHO-3
(Anti-Utr) demonstrated specific
enrichment for dystrophin and
utrophin. Dystrobrevin in these
preparations was identified with
DB13H1, a pan-specific mAb
(Anti-Db). Dystrophin and utro-
phin complexes purified with the
mAbs MANDRA-1 and MAN-
CHO-3, respectively, gave very
similar results (data not shown).
Molecular weight markers are
shown in kD.Peters et al. Regulated Pairing of Dystrobrevins with Dystrophin and Utrophin 1273
phin preparations contained predominantly an z65-kD
dystrobrevin (a-dystrobrevin-2), whereas the utrophin
preparations were highly enriched in an z84-kD dystro-
brevin (a-dystrobrevin-1). In each case, however, the specific
copurification was not absolute. Low levels of a-dystrobre-
vin-2 were detected in utrophin preparations, whereas dys-
trophin preparations contained very small amounts of
a-dystrobrevin-1. These results suggest that a-dystro-
brevins-1 and -2 are preferentially associated with utro-
phin and dystrophin, respectively.
Regulation of Dystrobrevin Isoform Pairing with 
Dystrophin and Utrophin
The association of a-dystrobrevin and dystrophin is medi-
ated by the coiled-coil regions found in both proteins (36).
Similar mechanisms probably drive the association of
utrophin and a-dystrobrevin. Thus, alternative splicing of
a-dystrobrevin sequences immediately adjacent to these
coiled-coils could alter the specificity of their interactions
with dystrophin and utrophin (10, 35). A related possibil-
ity is that other proteins that associate preferentially with
utrophin or dystrophin, or with the isoforms of a-dystro-
brevin, regulate the interactions. We have used several ap-
proaches, including association of in vitro–translated pro-
teins, yeast two-hybrid, and analysis of the distributions in
mice genetically altered in expression of utrophin and dys-
trophin to investigate these possibilities.
Association of In Vitro–translated Proteins
To test for specific associations of dystrobrevin isoforms
with dystrophin and utrophin, we studied the interaction
of in vitro–translated proteins (4). Recombinant proteins
corresponding to the COOH-terminal domains of dystro-
phin and utrophin (which contain the dystrobrevin binding
site) were incubated in pairwise combinations with recom-
binant full-length a-dystrobrevin-1 and -2, and then ana-
lyzed for the formation of complexes by immunoprecipita-
tion with Abs to one of the proteins. The dystrophin
construct (C2979) corresponds to amino acids 2,980–3,685
and gives rise to an 84-kD protein (4). The utrophin con-
struct (TDRII) corresponds to amino acids 2,753–3,432
and produces an 81-kD protein (4). The full-length a-dys-
trobrevin-l construct encodes exons 1–21 (amino acids 1–666)
and produces a 79-kD protein, whereas the a-dystrobre-
vin-2 construct contains exons 1–17B (amino acids 1–567)
and encodes a 68-kD product. The dystrobrevin proteins
were radiolabeled by incorporation of [14C]leucine and the
conditions of coprecipitation were optimized by using the
documented interactions of b1-syntrophin and dystrophin
or dystrobrevin (25, 28, 29, 36) (data not shown). Both
dystrobrevin isoforms tend to aggregate and to be immu-
noprecipitated non-specifically. Therefore, in each case, a
control immunoprecipitation reaction was included in
which either anti-dystrophin or anti-utrophin antibody
was omitted.
In vitro interactions between dystrobrevins and either
dystrophin or utrophin were found with this assay (Fig. 4).
An antibody directed against the COOH-terminal region
of dystrophin (Dys2) coprecipitated radiolabeled a-dys-
trobrevin-1 and a-dystrobrevin-2 in the presence of dys-
trophin (Fig. 4 A, lanes 3 and 5, respectively). By with-
holding from the reaction either cognate protein (data not
shown) or antibodies (Fig. 4 A, lanes 2 and 4), or by using
an antibody directed against the NH2 terminus of dystro-
phin (data not shown), precipitation of the complex was
significantly reduced. Thus, dystrophin appears to interact
with either a-dystrobrevin-1 or a-dystrobrevin-2. In a sim-
ilar experiment, utrophin coprecipitated with a-dystrobre-
vin-l, but not a-dystrobrevin-2 (Fig. 4 B, compare lanes 3
and 5). By withholding from the reaction either respective
cognate protein (data not shown) or antibodies (Fig. 4 B,
lanes 2 and 4), little or no dystrobrevin was coprecipitated.
To provide a more quantitative assessment of these in-
teractions, the coprecipitation experiments were repli-
cated five times and the amounts of dystrobrevins associ-
ated with either dystrophin or utrophin were determined
by band densitometry (Table I). These results confirmed
the findings shown in Fig. 4. a-Dystrobrevin-1 interacts
specifically with both dystrophin and utrophin. a-Dystro-
brevin-2 also interacts with dystrophin, but not with utro-
phin.
Yeast Two-Hybrid Analysis of Interactions
The preferential interaction of a-dystrobrevin-2 with dys-
trophin was also studied using the yeast two-hybrid system
Figure 4. Analysis of dystrobrevin–
dystrophin and dystrobrevin–utro-
phin interactions by coimmuno-
precipitation of in vitro–translated
proteins.  a-Dystrobrevin-1 or -2
was synthesized in the presence of
14C-leucine; utrophin and dystro-
phin were synthesized as non-radio-
active forms. In vitro–translated
proteins were incubated together,
and then precipitated with a specific
antibody in the presence of protein
G–Sepharose. After centrifugation
and washing, bound proteins were
eluted in sample buffer and ana-
lyzed by SDS-PAGE and autora-
diography. (A) Lane 1, [14C]methy-
lated molecular weight standards.
Lane  2, control in which radiolabeled a-dystrobrevin-1 was incu-
bated with dystrophin, but anti-dystrophin was excluded from the
immunoprecipitation. Lane 3, radiolabeled a-dystrobrevin-1 was
incubated with dystrophin and complexes were immunoprecipi-
tated with anti-dystrophin. Lane 4, control in which radiolabeled
a-dystrobrevin-2 was incubated with dystrophin, but anti-dystro-
phin was excluded from the immunoprecipitation. Lane 5, radio-
labeled a-dystrobrevin-2 was incubated with dystrophin and com-
plexes were immunoprecipitated with anti-dystrophin. (B) Lane
1, [14C]methylated molecular weight standards. Lane 2, control in
which radiolabeled a-dystrobrevin-1 was incubated with utro-
phin, but anti-utrophin was excluded from the immunoprecipita-
tion. Lane 3, radiolabeled a-dystrobrevin-1 was incubated with
utrophin and complexes were immunoprecipitated with anti-
utrophin. Lane 4, control in which radiolabeled a-dystrobrevin-2
was incubated with utrophin, but anti-utrophin was excluded
from the immunoprecipitation. Lane 5, radiolabeled a-dystrobre-
vin-2 was incubated with utrophin and complexes were immuno-
precipitated with anti-utrophin. A background of nonspecific ag-
gregation and precipitation of a-dystrobrevin-1 and -2 was seen,
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(Table II). a-Dystrobrevin-1 and -2 were each tested for
interactions with dystrophin, utrophin, and each other by
co-transforming into the Hf7c yeast strain a DNA-binding
domain plasmid (pGBT9) encoding one of the proteins
and an activation domain plasmid (pGAD) encoding the
other protein. In this assay, a-dystrobrevin-1 interacted
with both utrophin and dystrophin, while a-dystrobrevin-2
interacted only with dystrophin (Table II). These results
confirm those obtained with in vitro–translated proteins.
Distribution of Dystrobrevin Isoforms in Skeletal 
Muscle Lacking Dystrophin and Utrophin
The distribution and levels of dystrophin-associated pro-
teins in skeletal muscle are known to be altered by the ab-
sence of dystrophin (16, 28). Prominent examples of these
changes occur in skeletal muscle from humans with Du-
chenne muscular dystrophy and in the mdx mouse. At the
NMJ, however, dystrophin-associated proteins are re-
tained, probably because they are associated with utrophin
at this site. We have examined the distribution of a-dystro-
brevin isoforms in skeletal muscle from mdx mice, from
mice in which utrophin is absent because of targeted dis-
ruption of the gene (utrn2/2) (23), and from mice ob-
tained by crossing mdx and utrn2/2 mice, which thus lack
both dystrophin and utrophin (24).
For  a-dystrobrevin-2, different results were obtained
depending on the region of muscle examined. In regions
away from the neuromuscular synapses, staining for a-dys-
trobrevin-2 appears normal on the sarcolemma of skeletal
muscle from utrn2/2 mice, but is dramatically reduced on
the sarcolemma of mdx and mdx:utrn2/2 mice in regions
of muscle fibers away from the central zone where NMJs
are located (Fig. 5 A). This result suggests that association
with dystrophin is probably the major factor in the sar-
colemmal association of a-dystrobrevin-2. In contrast, la-
beling for a-dystrobrevin-2 is retained at NMJs and on the
perijunctional sarcolemma, even in mice lacking both dys-
trophin and utrophin (Fig. 5 B, left column). This labeling
presumably reflects retention of a-dystrobrevin-2. The al-
ternative possibility is that the labeling is due to a-dystro-
brevin-5, an NH2-terminal–truncated form that shares the
aDB2 epitope with a-dystrobrevin-2 (35). The only avail-
able evidence on this possibility is that a-dystrobrevin-5 is
not expressed at significant levels in normal skeletal mus-
cle. In either case, however, our result suggests that factors
in addition to dystrophin and utrophin are required in the
association of a-dystrobrevins with the perijunctional sar-
colemma (10, 35).
The synaptic localization of a-dystrobrevin-1 is retained
in mdx muscle, as expected if it is associated with utrophin.
However, synaptic staining of a-dystrobrevin-1 is also
present in muscles from utrn2/2 mice. Only when both
dystrophin and utrophin were eliminated from the post-
synaptic membrane was a-dystrobrevin-1 lost from the
synapse. These results suggest that a-dystrobrevin-1 is as-
sociated with both dystrophin and utrophin at the synapse,
an interaction consistent with the biochemical and yeast
two hybrid findings described above.
High Resolution Analysis of a-Dystrobrevins in the 
Postsynaptic Membrane
Within the NMJ, utrophin is sharply confined to the
AChR- and rapsyn-rich superficial zones, or crests, of the
junctional folds (8; see Fig. 6 G for a schematic representa-
tion). Dystrophin occurs in the deep portions of the folds
(13, 39), which are also the site of sodium channel concen-
tration (18). To determine whether this may also be true of
a-dystrobrevin-1 and a-dystrobrevin-2, we applied a high
resolution immunofluorescence method in which labeled
cryostat sections of mouse sternomastoid muscle are em-
bedded in Araldite, sectioned at 100-nm thickness and ex-
amined by confocal microscopy (Kramarcy, N.R., and R.
Sealock, manuscript in preparation).
A low magnification view of a muscle fiber stained with
Ab aDB638 against a-dystrobrevin-1 is shown in Fig. 6 A
(antibody staining in red, a-BgTx staining of AChRs in
green; overlap in yellow). As previously shown in Fig. 2,
NMJs were strongly labeled by Ab aDB638. Weak but
specific extrajunctional labeling was also consistently de-
Table I. Quantification of a-Dystrobrevin-Dystrophin and a-Dystrobrevin-Utrophin Coprecipitation
Expt.
 No.
Dys/aDB-1 Dys/aDB-2 Utr/aDB-1 Utr/aDB-2
2Ab 1Ab fold** 2Ab 1Ab fold 2Ab 1Ab fold 2Ab 1Ab fold
1 14,270* 38,134 2.7 17,995 66,851 3.7 19,449 60,339 3.1 14,009 18,355 1.3
2 884 1,918 2.2 1,057 4,411 4.2 33,097 134,637 4.0 47,288 44,523 0.9
3 47,436 170,415 3.6 487 1,865 3.8 2,966 8,904 3.0 2,638 1,974 0.8
4 9,493 28,209 3.0 20,182 67,344 3.3 3,840 13,792 3.6 1,343 1,472 1.1
5 19,009 61,822 3.3 1,124 3,565 3.2 3,451 9,940 2.9 1,244 1,277 1.0
3.0 3.6 3.3 1.0
Avg. (s 6 0.5) (s 6 0.4) (s 6 0.4) (s 6 0.2)
*The band activities were quantified with ImageQuant software and are in units pixel. The positive band activities of at least twofold over the background pixel values were easily
discernable.
**fold, Fold difference between the band activities of the reaction containing the specific antibody and the control experiment (no antibody).
Table II. a-Dystrobrevin-Dystrophin and
a-Dystrobrevin-Utrophin Interactions in the Yeast
Two-Hybrid Assay
Expressed
proteins Dystrophin Utrophin a-Dystrobrevin-1 a-Dystrobrevin-2
Dystrophin 22 22 11 11
Utrophin 22 22 11 22
a-Dystrobrevin-1 11 11 22 22
a-Dystrobrevin-2 11 22 22 22
22 5 no growth on selective media, and no positive b-galactosidase activity.
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tected by the thin-section method. At intermediate magnifi-
cations, the deep portions of the junctional folds were
labeled for both a-dystrobrevins-1 and -2 (Fig. 6, B and C,
respectively). Labeling for a-dystrobrevin-1, and to a lesser
extent for a-dystrobrevin-2, was also apparent in the recep-
tor- and utrophin-rich crests, as suggested by the yellow in
Figs. 6, B and C. Viewing of the separated red and green
channels at high magnification showed that the crests were
strongly labeled by Ab aDB638, while the deep portions
were also labeled, but more weakly (Fig. 6, E–E0). Ab
aDB2, against a-dystrobrevin-2, gave the opposite result:
the deep portions were strongly labeled, while the crests
were more weakly labeled, and labeled to various extents
(Fig. 6, D–D0). On the basis of these results, a-dystrobre-
vin-1 and a-dystrobrevin-2 appear to have distinct but
overlapping distributions within the NMJ. To test whether
the appearance of labeling on the crests reflected genuine
presence of antibody, rather than arising from the low reso-
lution of light microscopy, we concentrated on sections that
just grazed individual nerve–muscle contacts. Fig. 6 G
shows schematically why such views contain patches of
receptor-rich membrane only. An example from a junction
labeled with Ab aDB2 is shown in Fig. 6, F–F0. Overlapping
labels for receptor (Fig. 6 F) and a-dystrobrevin-2 (Fig. 6
F9) are clearly apparent. As in the transverse image (Figs. 6,
D–D0), the deep regions are more strongly labeled than the
crests. Greater than 90% of such images show distinct label-
ing of the receptor-rich zone by Ab aDB2. In contrast,
labeling for ankyrin G, a protein that has been shown quan-
titatively to be confined to the deep portions (18), is very
weak or absent from most en face views of the crests (Kra-
marcy, N.R., and R. Sealock, unpublished observations).
This suggests that the labeling of the crest region by Ab
aDB2 is accurate. Thus, a-dystrobrevin-2 is present on the
receptor-rich membranes but is most concentrated on the
receptor-poor membranes of the junction.
The presence of a-dystrobrevin-2 on the crests, albeit at
lower amounts than in the deep portions of the folds,
Figure 5. a-Dystrobrevins in
skeletal muscle from wild-
type,  mdx,  utrn2/2, and
mdx:utrn2/2  mice. (A) Sec-
tions of gastrocnemius muscle
lacking NMJs from wild-type
and genetically altered mice
were stained with antibody
to a-dystrobrevin-2 (aDB2).
Staining in wild-type (a) and
utrn2/2 muscle (b) were in-
distinguishable. In mdx ( c )
and  mdx:utrn2/2 ( d ) mus-
cles, the sarcolemmal stain-
ing of most fibers was greatly
diminished. (B) Sections of
gastrocnemius muscle con-
taining NMJs were double la-
beled with a-bungarotoxin
(a-BgTx) (primed letters)
and antibodies to a-dystro-
brevin-2 (a, c, e, g) or a-dys-
trobrevin-1 (b, d, f, h). Stain-
ing for a-dystrobrevin-2 in
the synaptic and perisynap-
tic membrane was essen-
tially unaffected by the ab-
sence of utrophin (utrn2/2),
dystrophin (mdx), or both
proteins (mdx:utrn2/2). Stain-
ing  for a-dystrobrevin-1 was
strong at synapses in wild-
type (wt), utrn2/2, and mdx
muscle, but was lost in the
double mutant. Bars: (c and
h9) 40 mm. The Journal of Cell Biology, Volume 142, 1998 1276
could be due to association of this isoform with utrophin.
This interaction may be of too low an affinity to be de-
tected by in vitro association or yeast two-hybrid analyses,
but could be driven by the high local concentrations of the
two proteins at the junction. Alternatively, occurrence of
a-dystrobrevin-2 on the crests could reflect its association
with other proteins, as in its persistence at the junction in
mdx:utrn2/2 mice.
Discussion
Originally identified as an 87-kD protein associated with
AChR-enriched membranes in Torpedo electric organ
(14), dystrobrevin was subsequently found to be related to
dystrophin and utrophin (43). Dystrophin and dystrobre-
vin are homologous throughout their CT and CR regions
(10, 36, 43). Although the extent of homology is rather
Figure 6. High resolution lo-
calization of a-dystrobre-
vin-1 and a-dystrobrevin-2 at
the NMJ. Cryostat sections
of mouse sternomastoid mus-
cle were double-labeled on
AChRs (with a-bungarotoxin;
green) and on a-dystrobre-
vins (antibodies; red), then
prepared for confocal mi-
croscopy.  Yellow, overlap of
strong red and green signals.
(A) Muscle fiber labeled with
Ab  aDb638, against a-dys-
trobrevin-1. The four nerve–
muscle contacts on the fiber
are strongly labeled (right-
hand side of the fiber). The
extrajunctional sarcolemma
is weakly labeled (arrows).
(B and C) Higher magnifica-
tion views of junctions la-
beled with Ab aDb2 against
a-dystrobrevin-2 (B) and Ab
aDb638 (C). The folds are
strongly labeled (arrows).
Extensive overlap of the red
and green labels on the crests
is suggested by the yellow.
(D–D0 and E–E0) Partial
views of single nerve–muscle
contacts labeled with Ab
aDb2 (D–D0) and Ab
aDb638 (E–E0). N, nerve
terminal. (D and E) The sep-
arated green channels show-
ing receptor labeling. (D9
and  E9) Red channels show-
ing antibody labeling. (D0
and E0) the combined red
and green channels. Arrows
pointing to the extracellular
side of the a-BgTx images in
D0 and E0 are reproduced at
equivalent positions in D and
D9, and in E and E9, respec-
tively. Ab aDb638 (a-dystro-
brevin-1) gave stronger la-
beling of the crests than the deep portions (E9), while Ab aDb2 (a-dystrobrevin-2) labeled the deep portions more strongly (D9). (F–F0)
En face view of a receptor-rich area in a cell labeled with Ab aDb2. Extensive overlap of a-BgTx and antibody labeling is apparent. The
deep portions of the folds, surrounding the toxin-labeled area, are more strongly labeled by the antibody than the crest area. (G) A
schematic representation of the sectioning that gives rise to en face views involving two adjacent folds. Green, receptor-rich membrane.
Red, antigen-rich membrane in the deep folds. Black, submembrane cytoskeletal specialization the antigen content of which is to be
evaluated. The parallel lines indicate, to scale, a plane of section that projects from the page; in the region shown, the section includes
receptor-rich regions, but no membrane from the deep folds. Double arrow, direction of viewing, parallel to the page. Gray, synaptic
basal lamina, presynaptic membrane, synaptic vesicles. Bars: (A) 8 mm; (B) 3.3 mm; (C) 2.8 mm; (D) 0.7 mm; (E), 0.6 mm; (F) 1.0 mm.Peters et al. Regulated Pairing of Dystrobrevins with Dystrophin and Utrophin 1277
low, defined sites for interaction with other proteins, in-
cluding the syntrophins, are highly similar. Outside the
CRCT domain, dystrophin and dystrobrevin are largely
unrelated. The actin-binding domain and spectrin-like re-
peats of dystrophin (and utrophin) are absent from dystro-
brevin, while the COOH-terminal extension of <180
amino acids of a-dystrobrevin-1 is not found in dystrophin
and utrophin. Thus, dystrobrevin and dystrophin may
serve similar functions through the CRCT domains, while
at the same time having different functions mediated by
their unique domains.
The demonstration that dystrobrevins are, in fact, dys-
trophin-associated proteins, an interaction mediated by
two coiled-coil heptad repeats in the COOH-terminal re-
gions of both proteins (36), formed the basis for a new
model of the dystrophin complex (28, 36). A key feature of
this model is the presence of two syntrophins, one bound
to dystrophin and one to dystrobrevin. Both syntrophins
are presumably available to bind via their PDZ domains to
signaling proteins such as neuronal nitric oxide synthase
and sodium channels (12, 21, 37). Consequently, the exist-
ence of multiple forms of a-dystrobrevin generated by al-
ternative splicing and the use of different promoters (10,
35), as well as a second, closely related protein, b-dystro-
brevin, encoded by a separate gene (11, 29, 30), implies
that the composition of proteins in the dystrophin com-
plex, and therefore the function of the complex, can be
quite diverse. In results reported here, we show that alter-
native splicing of a-dystrobrevin regulates its interaction
with dystrophin and utrophin, and that the unique COOH-
terminal extension of a-dystrobrevin-1 may have a special
function at the neuromuscular synapse.
The coiled-coil region of a-dystrobrevin that mediates
binding to dystrophin (36) and utrophin is identical in both
a-dystrobrevin-1 and -2. Thus, the selective interaction of
a-dystrobrevin-2 with dystrophin in in vitro association
and yeast two-hybrid tests was not anticipated. In part, the
specificity of the interactions between a-dystrobrevins and
dystrophin/utrophin is inherent in the structures of the
proteins themselves. The failure of a-dystrobrevin-2 to bind
recombinant utrophin suggests that sequences present in
this form prevent the coiled-coil–mediated interaction that
occurs between dystrophin or utrophin and a-dystrobre-
vin-1. A plausible explanation for this result is that se-
quences adjacent to the coiled-coils in a-dystrobrevin-1
are responsible for this regulation. Regions immediately
after the coiled-coils are subject to alternative splicing and,
depending on the exons used, a-dystrobrevin-1 and a-dys-
trobrevin-2 could differ significantly at this site (6, 10, 35).
In the same manner, the DUR or two additional splice sites
upstream of the coiled-coils could influence specificity.
The selective interaction of a-dystrobrevin-2 with dys-
trophin is entirely consistent with the copurification and
colocalization of these two proteins, and with the loss of
a-dystrobrevin-2 from the sarcolemma in mdx muscle.
Similarly, the ability of a-dystrobrevin-1 to bind both dys-
trophin and utrophin could explain the presence of a-dys-
trobrevin-1 throughout the junctional folds, its retention at
the synapse in mdx and utrn2/2, and its absence from the
junction in the double mutant. However, the retention of
a-dystrobrevin-2 at synaptic and perisynaptic sites in mus-
cle lacking both dystrophin and utrophin is not easily ex-
plained by these interactions. Rather, this finding implies
that  a-dystrobrevin-2 interacts with another protein at
these sites whose presence is independent of dystrophin or
utrophin. This protein could be another member of the
dystrophin family, a protein with a compatible coiled-coil
domain, or a protein that interacts with other regions of
a-dystrobrevin-2. This protein would not interact with
a-dystrobrevin-1, however, since this form is not present
at synapses in the double mutant.
Proteins at the neuromuscular synapse are generally
confined to a specific region of the postsynaptic folds (for
review see reference 38). The segregation of nicotinic re-
ceptors at the crests and sodium channels in the bottoms
of the folds are classic examples. Submembrane proteins,
such as rapsyn and utrophin at the crests and dystrophin in
the bottoms of the folds, are similarly distributed. In this
sense,  a-dystrobrevin-1 is unusual in that it is found
throughout the folds. Thus, its function, while likely to be
synaptically related, probably is not unique to either so-
dium channels or nicotinic receptors. The synaptic func-
tion of a-dystrobrevin-1 most likely involves the DUR,
which contains numerous potential sites for tyrosine phos-
phorylation. Tyrosine phosphorylation stimulated by agrin
activation of a muscle-specific kinase has been linked to
synapse formation (7, 15, 22). Although Torpedo dystro-
brevin is endogenously phosphorylated on tyrosine (43),
neither the identity of the kinase(s) responsible for its
phosphorylation nor the downstream consequences are
known.
The association of particular a-dystrobrevin isoforms
with dystrophin or utrophin is not random, but rather ap-
pears to be highly regulated. Furthermore, this regulatory
event may be important for targeting of dystrophin or
utrophin complexes to different membrane domains. Al-
though much less is known about the existence of alterna-
tively spliced forms of b-dystrobrevin, similar regulation
of its interaction with dystrophin and utrophin may occur.
The wide expression of a-dystrobrevin-1 and -2 (and other
isoforms) and b-dystrobrevin in a variety of tissues sug-
gests that targeting to specialized membrane domains may
occur in many cell types. Thus, the assembly of multi-com-
ponent complexes containing dystrophin, utrophin, and
dystrobrevin, and their associated signaling proteins, may
be a common feature of specialized membrane domains in
many cell types.
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